Alaunos Therapeutics Inc (TCRT) Stock Price, Quote & News

Company Profile

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos T...

Industry: Biotechnology

Sector: Healthcare

Phone: 346 355 4099

Website: www.alaunos.com

Address:

2617 Bissonnet Street, Suite 233, Houston, United States

mikesterz7 May. 26 at 11:51 PM

$TCRT Preclinical findings for obesity drug candidate ALN1003 showed metabolic improvements, adding to interest in next-generation treatments beyond GLP-1 drugs. PT 5

0 · Reply

focafoca99 May. 26 at 6:34 PM

$TCRT shared an integrated preclinical readout for its obesity drug candidate ALN1003.

0 · Reply

StocktwitsNews May. 26 at 6:05 PM

Alaunos Reports Positive Preclinical Obesity Drug Results Across Weight, Liver, Insulin Markers $TCRT https://stocktwits.com/news/equity/markets/alaunos-therapeutics-tcrt-obesity-drug-study-weight-loss-liver-health-preclinical-aln1003/cZgOaMJReqA

0 · Reply

focafoca99 May. 26 at 3:46 PM

$TCRT released preclinical data showing ALN1003 cuts weight, improves insulin sensitivity and reduces liver fat in obese mice.

0 · Reply

OfficialStocktwitsUser May. 21 at 1:10 AM

$TCRT RSI: 39.73, MACD: -0.1030 Vol: 0.10, MA20: 2.58, MA50: 2.84 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

focafoca99 May. 18 at 12:26 PM

$TCRT communicated updated preclinical data on ALN1003, its oral obesity therapeutic candidate.

0 · Reply

Estimize May. 14 at 10:00 AM

$TCRT reported - EPS and - revenue for Q1. http://www.estimize.com/intro/tcrt?chart=historical&metric_name=eps&utm_content=TCRT&utm_medium=

0 · Reply

BillionerOfKing May. 1 at 1:20 AM

$TCRT Current Stock Price: $2.55

0 · Reply

eman1200 Apr. 30 at 4:39 PM

$TCRT has this been delisted or something?

0 · Reply

focafoca99 Apr. 15 at 9:13 PM

$TCRT disclosed a Nasdaq notice for failing the minimum stockholders' equity requirement and said it plans to submit a compliance plan.

0 · Reply

Alaunos Therapeutics reports metabolic improvements with ALN1003 in studies

May 26, 2026, 11:01 AM EDT - 3 days ago

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

2026-05-18T12:26:37.000Z - 11 days ago

Alaunos Therapeutics reports updated preclinical data from ALN1003 mouse studies

May 18, 2026, 8:00 AM EDT - 11 days ago

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

May 15, 2026, 7:00 AM EDT - 14 days ago

Alaunos Therapeutics Quarterly report: Q1 2026

May 4, 2026, 4:05 PM EDT - 25 days ago

Valion Bio Appoints Melinda Lackey as General Counsel

VBIO

Mar 31, 2026, 7:00 AM EDT - 2 months ago

Alaunos Therapeutics Annual report: Q4 2025

2026-03-02T11:43:28.000Z - 3 months ago

Alaunos Therapeutics reports ‘positive’ proof-of-concept data for ALN1003

Mar 2, 2026, 6:30 AM EST - 3 months ago

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

Nov 14, 2025, 4:00 PM EST - 7 months ago

Alaunos Therapeutics Quarterly report: Q3 2025

Nov 7, 2025, 7:00 AM EST - 7 months ago

Alaunos Therapeutics Registration statement: Registration Filing

Oct 22, 2025, 8:00 AM EDT - 7 months ago

Alaunos Therapeutics Registration statement: Registration Filing

2025-10-22T10:40:47.000Z - 7 months ago

Alaunos Therapeutics files to sell 327,740 shares of common for holders

Oct 2, 2025, 8:00 AM EDT - 8 months ago

Alaunos Therapeutics Registration statement: Registration Filing

Sep 9, 2025, 8:00 AM EDT - 9 months ago

Alaunos Therapeutics Registration statement: Registration Filing

Aug 21, 2025, 8:00 AM EDT - 10 months ago

Alaunos Therapeutics Registration statement: Registration Filing

2025-08-21T10:10:16.000Z - 10 months ago

Alaunos Therapeutics files $50M mixed securities shelf

Aug 14, 2025, 7:00 AM EDT - 10 months ago

Alaunos Therapeutics Quarterly report: Q2 2025

2025-06-23T17:00:26.000Z - 1 year ago

Alaunos prices 610,399 shares at $3.36 in registered direct offering

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

May 21, 2025, 8:00 AM EDT - 1 year ago

Alaunos Therapeutics Proxy statement: Proxy Filing

May 21, 2025, 8:00 AM EDT - 1 year ago

Alaunos Therapeutics Proxy statement: Proxy Filing

May 15, 2025, 12:30 PM EDT - 1 year ago

Alaunos Therapeutics Quarterly report: Q1 2025

2025-05-14T12:19:01.000Z - 1 year ago

PMGC Capital announces filing to report 5.09% stake in Alaunos Therapeutics

ELAB

May 14, 2025, 8:00 AM EDT - 1 year ago

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

ELAB

May 9, 2025, 8:00 AM EDT - 1 year ago

Alaunos Therapeutics Proxy statement: Proxy Filing

Mar 30, 2025, 6:00 PM EDT - 1 year ago

Alaunos Therapeutics Annual report: Q4 2024

Nov 14, 2024, 9:30 AM EST - 1 year ago

Alaunos Therapeutics Quarterly report: Q3 2024

Aug 13, 2024, 6:00 PM EDT - 1 year ago

Alaunos Therapeutics Quarterly report: Q2 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

Alaunos Therapeutics Quarterly report: Q1 2024

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Alaunos Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Alaunos Therapeutics Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Alaunos Therapeutics Proxy statement: Proxy Filing

Apr 1, 2024, 9:30 AM EDT - 2 years ago

Alaunos Therapeutics Earnings release: Q4 2023

Apr 1, 2024, 9:30 AM EDT - 2 years ago

Alaunos Therapeutics Annual report: Q4 2023

Nov 14, 2023, 9:30 AM EST - 2 years ago

Alaunos Therapeutics Quarterly report: Q3 2023

Nov 14, 2023, 9:30 AM EST - 2 years ago

Alaunos Therapeutics Earnings release: Q3 2023

2023-11-14T12:35:47.000Z - 2 years ago

Alaunos Therapeutics reports Q3 EPS (4c) vs (4c) last year

Nov 14, 2023, 7:30 AM EST - 2 years ago

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

2023-08-16T12:35:15.000Z - 3 years ago

Alaunos Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

2023-08-15T13:51:04.000Z - 3 years ago

Alaunos Therapeutics downgraded to Hold from Buy at Laidlaw

2023-08-14T20:46:51.000Z - 3 years ago

Alaunos Therapeutics reports Q2 EPS (4c), consensus (4c)

Aug 14, 2023, 4:05 PM EDT - 3 years ago

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Alaunos Therapeutics Quarterly report: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Alaunos Therapeutics Earnings release: Q2 2023

Jun 29, 2023, 7:00 AM EDT - 3 years ago

Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies

May 25, 2023, 5:00 PM EDT - 3 years ago

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

May 10, 2023, 9:00 AM EDT - 3 years ago

Alaunos Therapeutics Earnings Call Transcript: Q1 2023

May 10, 2023, 9:00 AM EDT - 3 years ago

Alaunos Therapeutics Quarterly report: Q1 2023

May 10, 2023, 9:00 AM EDT - 3 years ago

Alaunos Therapeutics Earnings release: Q1 2023

May 10, 2023, 7:00 AM EDT - 3 years ago

Alaunos Therapeutics Reports First Quarter 2023 Financial Results

May 3, 2023, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023

Apr 26, 2023, 12:30 PM EDT - 3 years ago

Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Alaunos Therapeutics Proxy statement: Proxy Filing

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Alaunos Therapeutics Proxy statement: Proxy Filing

Apr 14, 2023, 8:00 AM EDT - 3 years ago

Alaunos Therapeutics Proxy statement: Proxy Filing

2023-04-03T20:32:42.000Z - 3 years ago

Precigen amends exclusive license agreement with Alaunos Therapeutics

PGEN

2023-03-30T11:19:27.000Z - 3 years ago

Alaunos Therapeutics appoints Hofmeister to board of directors

Mar 30, 2023, 7:00 AM EDT - 3 years ago

Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors

Mar 29, 2023, 5:30 PM EDT - 3 years ago

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April

Mar 7, 2023, 8:30 AM EST - 3 years ago

Alaunos Therapeutics Earnings Call Transcript: Q4 2022

Mar 7, 2023, 8:30 AM EST - 3 years ago

Alaunos Therapeutics Annual report: Q4 2022

Mar 7, 2023, 8:30 AM EST - 3 years ago

Alaunos Therapeutics Earnings release: Q4 2022

Mar 7, 2023, 7:00 AM EST - 3 years ago

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Feb 28, 2023, 4:01 PM EST - 3 years ago

Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023

Jan 9, 2023, 8:30 AM EST - 3 years ago

Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023

Nov 29, 2022, 9:01 AM EST - 3 years ago

Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock

Nov 28, 2022, 4:01 PM EST - 3 years ago

Alaunos Therapeutics Announces Proposed Public Offering of Common Stock

Nov 14, 2022, 8:30 AM EST - 3 years ago

Alaunos Therapeutics Earnings Call Transcript: Q3 2022

Nov 14, 2022, 8:30 AM EST - 3 years ago

Alaunos Therapeutics Quarterly report: Q3 2022

Nov 14, 2022, 8:30 AM EST - 3 years ago

Alaunos Therapeutics Earnings release: Q3 2022

Nov 14, 2022, 8:30 AM EST - 3 years ago

Alaunos Therapeutics Slides: Q3 2022

Nov 14, 2022, 7:00 AM EST - 3 years ago

Alaunos Therapeutics Reports Third Quarter 2022 Financial Results

Nov 8, 2022, 8:30 AM EST - 3 years ago

Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022

Nov 7, 2022, 8:00 AM EST - 3 years ago

Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting

Sep 21, 2022, 8:30 AM EDT - 4 years ago

Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Sep 7, 2022, 8:30 AM EDT - 4 years ago

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 31, 2022, 8:00 AM EDT - 4 years ago

Alaunos Therapeutics Registration statement: Registration Filing

Aug 24, 2022, 3:00 PM EDT - 4 years ago

Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Aug 15, 2022, 7:30 AM EDT - 4 years ago

Alaunos Therapeutics Earnings Call Transcript: Q2 2022

Aug 15, 2022, 7:30 AM EDT - 4 years ago

Alaunos Therapeutics Quarterly report: Q2 2022

Aug 15, 2022, 7:30 AM EDT - 4 years ago

Alaunos Therapeutics Earnings release: Q2 2022

Aug 15, 2022, 7:00 AM EDT - 4 years ago

Alaunos Therapeutics Reports Second Quarter 2022 Financial Results

Aug 12, 2022, 8:00 AM EDT - 4 years ago

Alaunos Therapeutics Registration statement: Registration Filing

Aug 8, 2022, 8:50 AM EDT - 4 years ago

Alaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022

Aug 4, 2022, 5:00 PM EDT - 4 years ago

Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations

Jun 1, 2022, 11:39 AM EDT - 4 years ago

CellChorus Announces Scientific Advisory Board

Jun 1, 2022, 8:30 AM EDT - 4 years ago

Alaunos Therapeutics to Present at the Jefferies Healthcare Conference

May 26, 2022, 5:01 PM EDT - 4 years ago

Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting

May 16, 2022, 8:43 AM EDT - 4 years ago

Alaunos Therapeutics Earnings Call Transcript: Q1 2022

May 16, 2022, 8:43 AM EDT - 4 years ago

Alaunos Therapeutics Quarterly report: Q1 2022

May 16, 2022, 7:30 AM EDT - 4 years ago

Alaunos Therapeutics Reports First Quarter 2022 Financial Results

May 10, 2022, 8:30 AM EDT - 4 years ago

Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference

May 9, 2022, 8:30 AM EDT - 4 years ago

Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022

May 2, 2022, 4:31 PM EDT - 4 years ago

Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting

May 2, 2022, 8:30 AM EDT - 4 years ago

Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors

Apr 27, 2022, 8:00 AM EDT - 4 years ago

Alaunos Therapeutics Proxy statement: Proxy Filing

Apr 27, 2022, 8:00 AM EDT - 4 years ago

Alaunos Therapeutics Proxy statement: Proxy Filing

Apr 15, 2022, 8:00 AM EDT - 4 years ago

Alaunos Therapeutics Proxy statement: Proxy Filing

Mar 30, 2022, 8:00 AM EDT - 4 years ago

Alaunos Therapeutics Annual report: Q4 2021

Mar 30, 2022, 7:30 AM EDT - 4 years ago

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Mar 16, 2022, 8:30 AM EDT - 4 years ago

Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022

Mar 8, 2022, 4:05 PM EST - 4 years ago

Alaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Jan 26, 2022, 7:00 AM EST - 4 years ago

Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics

Nov 9, 2021, 8:05 AM EST - 4 years ago

Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting

Nov 8, 2021, 4:10 PM EST - 4 years ago

Ziopharm Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update

Nov 1, 2021, 4:30 PM EDT - 4 years ago

Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021

Sep 27, 2021, 4:05 PM EDT - 5 years ago

Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway

Sep 1, 2021, 4:05 PM EDT - 5 years ago

Ziopharm Oncology to Participate in September Investor Conferences

Aug 30, 2021, 8:30 AM EDT - 5 years ago

Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions

Jul 26, 2021, 4:30 PM EDT - 5 years ago

Ziopharm Oncology to Report Second Quarter Financial Results on August 9, 2021

May 24, 2021, 4:05 PM EDT - 5 years ago

Ziopharm Oncology to Participate in Upcoming Conferences

May 19, 2021, 4:05 PM EDT - 5 years ago

Ziopharm Oncology Reinforces Clear and Bold Vision for Delivering Value at Annual Shareholders Meeting

mikesterz7 May. 26 at 11:51 PM

$TCRT Preclinical findings for obesity drug candidate ALN1003 showed metabolic improvements, adding to interest in next-generation treatments beyond GLP-1 drugs. PT 5

0 · Reply

focafoca99 May. 26 at 6:34 PM

$TCRT shared an integrated preclinical readout for its obesity drug candidate ALN1003.

0 · Reply

StocktwitsNews May. 26 at 6:05 PM

0 · Reply

focafoca99 May. 26 at 3:46 PM

$TCRT released preclinical data showing ALN1003 cuts weight, improves insulin sensitivity and reduces liver fat in obese mice.

0 · Reply

OfficialStocktwitsUser May. 21 at 1:10 AM

0 · Reply

focafoca99 May. 18 at 12:26 PM

$TCRT communicated updated preclinical data on ALN1003, its oral obesity therapeutic candidate.

0 · Reply

Estimize May. 14 at 10:00 AM

$TCRT reported - EPS and - revenue for Q1. http://www.estimize.com/intro/tcrt?chart=historical&metric_name=eps&utm_content=TCRT&utm_medium=

0 · Reply

BillionerOfKing May. 1 at 1:20 AM

$TCRT Current Stock Price: $2.55

0 · Reply

eman1200 Apr. 30 at 4:39 PM

$TCRT has this been delisted or something?

0 · Reply

focafoca99 Apr. 15 at 9:13 PM

$TCRT disclosed a Nasdaq notice for failing the minimum stockholders' equity requirement and said it plans to submit a compliance plan.

0 · Reply

OfficialStocktwitsUser Feb. 23 at 3:07 PM

$TCRT RSI: 49.32, MACD: -0.1003 Vol: 0.14, MA20: 2.66, MA50: 3.11 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

topstockalerts Feb. 23 at 3:01 PM

$TCRT Holding firm at these levels. Buyers keep stepping in on dips. This shows real demand.

0 · Reply

BillionerOfKing Feb. 11 at 11:48 AM

$TCRT Current Stock Price: $2.78

0 · Reply

NVDAMillionaire Feb. 4 at 7:14 AM

$TCRT Great piece that accurately captures TCRT's current position. So if you want to refresh your understanding of TCRT or learn about TCRT for the first time, this is essential reading. https://everyticker.com/quote/TCRT/analysis/tcrt-s-existential-gamble-a-micro-cap-biotech-bets-its-remaining-cash-on-preclinical-obesity-nasdaq-tcrt

0 · Reply

CryptoKatt Jan. 2 at 11:22 AM

$TCRT What happened to Ziopharm and captain Kirk?

0 · Reply

CloudCharm Dec. 27 at 2:16 PM

$TCRT Positioning reflects caution while awaiting confirmable progress; unit economics must show steady improvement — a credible cadence of milestones would shift sentiment. The thesis tightens only when delivery matches ambition.

0 · Reply

CryptoKatt Dec. 23 at 3:36 PM

$TCRT Rob Cos still pumping this pos?

0 · Reply